Literature DB >> 6130003

Antihypertensive actions of an isomer of labetalol and other vasodilator-beta-adrenoceptor blockers.

T Baum, E J Sybertz.   

Abstract

Combinations of beta-adrenoceptor blockers and vasodilators have proved highly useful in antihypertensive therapy. Studies of the mechanisms of action of several agents that combine these effects within a single molecule are described in this report. Labetalol, SCH 19927, sulfinalol, MK-761, pindolol, and prizidilol, in contrast to propranolol, decreased blood pressure of spontaneously hypertensive rats (SHR). All except labetalol and SCH 19927 increased heart rate. In anesthetized dogs, all of these agents (except propranolol) produced vasodilatation on intra-arterial administration into the femoral vascular bed and, given i.v., lowered blood pressure after ganglionic blockade. In contrast to the other agents, labetalol and SCH 19927 caused only minimal increases in heart rate in ganglionically blocked dogs. The vasodilator and hypotensive actions as well as the antihypertensive effect in SHR of labetalol, SCH 19927, sulfinalol, and pindolol were inhibited by propranolol pretreatment but those of prizidilol were not, suggesting that the hypotensive and vascular effects of labetalol, SCH 19927, sulfinalol, pindolol, and MK-761 are mediated by activation of vascular beta-receptors. However, labetalol and SCH 19927 in particular differ from agents of this class as well as other beta blockers with strong intrinsic sympathomimetic actions in that their agonist activity is primarily directed at blood vessels and not the heart.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6130003

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  11 in total

1.  Impact of dilevalol on haemodynamic changes during emotional stress.

Authors:  H Rüddel; W Langewitz; M Bähr; M Düsterwald; H Schächinger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Haemodynamic effects of new beta-blockers with vasodilatory properties in essential hypertension.

Authors:  H Tsukiyama; K Otsuka; M Horii
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Labetolol in patients with hypertension and varying degrees of renal impairment.

Authors:  E G Breen; M Lombard; A Watson; J A Keogh
Journal:  Ir J Med Sci       Date:  1984-10       Impact factor: 1.568

6.  Propranolol versus labetalol: interesting differences in efficacy.

Authors:  W Flamenbaum
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

Review 7.  Pharmacology of antihypertensive agents with multiple actions.

Authors:  P A van Zwieten
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

Authors:  P Lund-Johansen; P Omvik
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

9.  A comparison of dilevalol and placebo in the management of isolated systolic hypertension using ambulatory monitoring.

Authors:  C A Silagy; J J McNeil; S Farish; B P McGrath
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

Review 10.  The role of multiple action agents in hypertension.

Authors:  P Lund-Johansen; P Omvik
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.